Environmental risk assessment of replication competent viral vectors applied in clinical trials: Potential effects of inserted sequences

Current Gene Therapy

Volumn 13, Issue 6, 2013, Pages 395-412

  van den Akker, Eric ^a   van der Vlugt, Cécile J B ^a   Bleijs, Diederik A ^a   Bergmans, Hans E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Bioinformatics; Environmental risk assessment; Genetically modified organism; Potentially hazardous gene product; Replication competent viral vector

Indexed keywords

REPLICATION COMPETENT VIRAL VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

BIOINFORMATICS; DNA MODIFICATION; ENVIRONMENTAL FACTOR; GENE PRODUCT; HAZARD ASSESSMENT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIFE CYCLE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TRANSGENIC ORGANISM; VACCINATION; VIRAL TROPISM; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS RECOMBINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DNA REPLICATION; DNA TRANSPOSABLE ELEMENTS; GENETIC THERAPY; GENETIC VECTORS; HAZARDOUS SUBSTANCES; HUMANS; RISK ASSESSMENT; VIRUS REPLICATION;

EID: 84891794268     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652321306140103221621     Document Type: Review

References (117)

1. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein L. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9(10):910-21.
2. Bleijs D. Workshop on shedding data from gene therapy studies with viral vectors. Amsterdam, January 22, 2004. J Gene Med 2005; 7(2):256-9.
3. van den Akker H. Environmental risk assessment of replication competent viral vectors in gene therapy trials. RIVM. 2008. Available at: http://www.rivm.nl/bibliotheek/rapporten/601850001.pdf. Access date 23-07-2013.
4. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9(12):1022-35.
5. Deliberate Release and Placing on the EU Market of GMOs-GMO Register. Available at: http://gmoinfo.jrc.ec.europa.eu/gmo_ browse.aspx. Access date 23-07-2013 and 24-09-2013.
6. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005; 11(2):180-95.
7. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther 2005; 5(4):429-43.
8. Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997; 90(5):849-57.
9. Johnson JE, Schnell MJ, Buonocore L, Rose JK. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 1997; 71(7):5060-8.
10. Patterson LJ, Prince GA, Richardson E, Alvord WG, Kalyan N, Robert-Guroff M. Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 2002; 292(1):107-13.
11. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18(7):1001-11.
12. Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012; 39(3):296-304.
13. Au G, Barry, RD, Shafren DR. Oncolytic virotherapy: a brief review. Drugplus International 2005; June/July 2005.
14. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001; 7(7):781-7.
15. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5(12):965-76.
16. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105(9):1169-72.
17. Liu TC, Kirn D. Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene 2005; 24(40):6069-79.
18. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24(52):7802-16.
19. van den Akker H. Environmental risk assessment of replication competent viral vectors in gene therapy trials. Supplementary document: Overview of replication competent viral vectors. RIVM. 2008. Available from: http://www.rivm.nl/bibliotheek/rapporten/ 601850002.pdf. Access date 23-07-2013.
20. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res 2006; 16(1):25-30.
21. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10(16):5299-312.
22. Wang F, Wang Z, Tian H, et al. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr Gene Ther 2012; 12(2):67-76.
23. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575(1-3):1-14.
24. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110(4):475-80.
25. Hedley SJ, Chen J, Mountz JD, et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother 2006; 55(11):1412-9.
26. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 2005; 24(52):7775-91.
27. Jiang H, Fueyo J. Eradication of brain tumor stem cells with an oncolytic adenovirus. Discov Med 2010; 10(50):24.
28. Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol Ther 2009; 17(3):409-16.
29. Committee for the medicinal product for human use (CHMP). Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products. EMA. 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/ Scientific_guideline/2009/09/WC500003964.pdf. Access date 23-07-2013.
30. Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official Journal of the European Communities 2001(17.4.2001):L106/1.
31. Hill RA. Conceptualizing risk assessment methodology for genetically modified organisms. Environ Biosafety Res 2005; 4(2):67-70.
32. Rudelsheim PLJ, Smets G. Methodology for environmental risk assessments in medical and veterinary biotechnology (CGM 2012-04). 2012. Available at: http://www.cogem.net/index.cfm/nl/ publicaties/ publicatie/methodology-for-environmental-risk-assessmentsin-medical-and-veterinary-biotechnology-l. Access date 23-07-2013.
33. Baldo, A, van den Akker, E, Bergmans, H, Lim, F, Pauwels, K. General consideration for the biosafety of virus-derived vectors used in gene therapy and vaccination Curr Gene Ther 2013; 13(6); 385-94.
34. Dutch GMO license database on deliberate release. Available at http://www.ggo-vergunningverlening.nl/Vergunningendatabase. Access date 23-07-2013.
35. Bergmans H, Logie C, Van Maanen K, Hermsen H, Meredyth M, Van Der Vlugt C. Identification of potentially hazardous human gene products in GMO risk assessment. Environ Biosafety Res 2008; 7(1):1-9.
36. Louz D, Bergmans HE, Loos BP, Hoeben RC. Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines. J Gene Med 2005; 7(10):1263-74.
37. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122(6):863-71.
38. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells. Sci Transl Med 2013; 5(197):197ra03.
39. Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R. An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res 2007; 67(23):11309-16.
40. OMIM. Online Mendelian Inheritance in Man. An Online Catalog of Human Genes and Genetic Disorders. Available at: http://omim.org/. Access date 23-07-2013.
41. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. J Biomed Biotechnol 2010; 2010:218590.
42. McFadden G, Mohamed MR, Rahman MM, Bartee E. Cytokine determinants of viral tropism. Nat Rev Immunol 2009; 9(9):645-55.
43. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62(5):1266-70.
44. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95(9):652-60.
45. Rudelsheim PLJ, Smets G. Gene therapy clinical trials: what about the environment? A comparison between the Netherlands and North America (CGM 2012-07). 2012. Available at: http:// www.cogem.net/index.cfm/en/publications/publicatie/genetherapy-clinical-trials-what-about-the-environment-a-comparisonbetween-the-netherlands-and-north-america. Access date 23-07-2013.
46. Aerts Kaya F, Kaptein L, Wagemaker G. Immune modulation in gene therapy studies-Points to consider for Environmental Risk Assessment. Erasmus MC. 2010. Available at: http:// repub. eur.nl/res/pub/21967/. Access date 23-07-2013.
47. Stanford MM, McFadden G. The 'supervirus'? Lessons from IL-4-expressing poxviruses. Trends Immunol 2005; 26(6):339-45.
48. Talbot TR, Peters J, Yan L, Wright PF, Edwards KM. Optimal bandaging of smallpox vaccination sites to decrease the potential for secondary vaccinia transmission without impairing lesion healing. Infect Control Hosp Epidemiol 2006; 27(11):1184-92.
49. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19(3):329-36.
50. Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20(4):749-58.
51. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28(7):1099-105.
52. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37(2):251-71.
53. Neff J, Modlin J, Birkhead GS, et al. Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board. Clin Infect Dis 2008; 46 Suppl 3:S258-70.
54. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6(6):611-23.
55. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274(5286):373-6.
56. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8(4):308-15.
57. Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004; 10(24):3634-8.
58. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 2011; 11(3):189-217.
59. Cheng WS, Dzojic H, Nilsson B, Totterman TH, Essand M. An oncolytic conditionally replicating adenovirus for hormonedependent and hormone-independent prostate cancer. Cancer Gene Ther 2006; 13(1):13-20.
60. Klinische studie met een conditioneel-replicerende adenovirale vector als aanvullende behandeling van prostaatkanker (CGM/120710-01). COGEM. 2012. Available at: http:// www.cogem.net/index.cfm/nl/publicaties/publicatie/klinischestudie-met-een-conditioneel-replicerende-adenovirale-vector-alsaanvullende-behandeling-van-prostaatkanker. Access date 25-09-2013.
61. Henken F, Oosterhuis K, Öhlschläger P, et al. Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. Vaccine 2012; 30(28):4259-66.
62. Daemen T, Regts J, Holtrop M, Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 2002; 9(2):85-94.
63. Toth K, Spencer JF, Tollefson AE, et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16(1):139-46.
64. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19(1):2-12.
65. Page JG, Tian B, Schweikart K, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007; 196(4):389 e1-9; discussion e9-10.
66. Kimball KJ, Preuss MA, Barnes MN, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010; 16(21):5277-87.
67. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215(3):403-10.
68. Pearson WR. Comparison of methods for searching protein sequence databases. Protein Sci 1995; 4(6):1145-60.
69. ExPASy Bioinformatics Resource Portal. Available at http:// www.expasy.org/. Access date 23-07-2013.
70. Finn RD, Mistry J, Tate J, et al. The Pfam protein families database. Nucleic Acids Res 2010; 38(suppl 1):D211-D22.
71. Cerami EG, Gross BE, Demir E, et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 2011; 39(suppl 1):D685-D90.
72. D'Eustachio P. Reactome knowledgebase of human biological pathways and processes. Methods Mol Biol 2011; 694:49-61.
73. Saier MH, Yen MR, Noto K, Tamang DG, Elkan C. The transporter classification database: recent advances. Nucleic Acids Res 2009; 37(suppl 1):D274-D8.
74. Francke C. The potential of applying bioinformatics approaches in the risk assessment of genes that lack a function annotation (CGM 2012-03). 2012. Available at: http://www.cogem.net/index.cfm/en/ publications/publicatie/cogem-research-report-cgm-2012-03. Access date 23-07-2013.
75. George RA, Heringa J. Protein domain identification and improved sequence similarity searching using PSI-BLAST. Proteins 2002; 48(4):672-81.
76. Iyer LM, Aravind L, Bork P, Hofmann K, Mushegian AR, Zhulin IB, et al. Quod erat demonstrandum? The mystery of experimental validation of apparently erroneous computational analyses of protein sequences. Genome Biol 2001; 2(12):1-0051.11.
77. Rost B. Enzyme function less conserved than anticipated. J Mol Biol 2002; 318(2):595-608.
78. Bharatham K, Zhang ZH, Mihalek I. Determinants, discriminants, conserved residues-a heuristic approach to detection of functional divergence in protein families. PloS One. 2011; 6(9):e24382.
79. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. Multiple sequence alignment with Clustal X. Trends Biochem Sci 1998; 23(10):403.
80. He B, Gross M, Roizman B. The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells. J Biol Chem 1998; 273(33):20737-43.
81. Nguyen TT, Goins, W.F. and Chiocca, E.A. Design of oncolytic HSV1 that express cellular gene moieties that improve antiglioma efficacy and normal cell safety (Abstract 690). In Late breaking abstracts-Addendum. ASGCT. 2013. Available at: http:// www.asgct.org/UserFiles/LateBreakingAbstractsAddendumrev2. pdf. Access date 23-07-2013.
82. Ottolino-Perry K, Diallo J-S, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2009; 18(2):251-63.
83. Sussman MD, Lu Z, Kutish G, Afonso CL, Roberts P, Rock DL. Identification of an African swine fever virus gene with similarity to a myeloid differentiation primary response gene and a neurovirulence-associated gene of herpes simplex virus. J Virol 1992; 66(9):5586-9.
84. Stone JD, Kranz DM. Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol 2013; 4:244.
85. Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. EFSA. 2011. Available at: http://www.efsa.europa.eu/en/ efsajournal/ pub/2193.htm. Access date 23-07-2013.
86. Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA. U.S. Government. 2010. Available at: http:// www.phe.gov/preparedness/legal/guidance/syndna/Pages/default.as px. Access date 23-07-2013.
87. Wang W, Wang Y. Equipping CAR-modified T cells with a brake to prevent chronic adverse effects. Curr Gene Ther 2012; 12(6):493-5.
88. Marin V, Cribioli E, Philip B, et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 2012; 23(6):376-86.
89. Wildner O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 2000; 60(15):4167-74.
90. Kennedy PG, Gairns J, MacLean AR. Replication of the herpes simplex virus type 1 RL1 mutant 1716 in primary neuronal cell cultures--possible relevance to use as a viral vector. J Neurol Sci 2000; 179(1-2):108-14.
91. Kesari S, Lasner TM, Balsara KR, et al. A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J Gen Virol 1998; 79(Pt 3):525-36.
92. Kesari S, Randazzo BP, Valyi-Nagy T, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73(5):636-48.
93. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57(13):2559-63.
94. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 2000; 97(12):6803-8.
95. Paielli DL, Wing MS, Rogulski KR, et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 2000; 1(3):263-74.
96. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11(1):67-76.
97. Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther 2001; 8(15):1142-8.
98. Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther 2001; 8(15):1132-41.
99. Lee YS, Kim JH, Choi KJ, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12(19):5859-68.
100. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53(2):109-17.
101. Lamfers ML, Gianni D, Tung CH, et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res 2005; 65(20):9398-405.
102. Heideman DA, Steenbergen RD, van der Torre J, et al. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol Ther 2005; 12(6):1083-90.
103. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002; 62(21):6165-71.
104. Ganesh S, Gonzalez Edick M, Idamakanti N, et al. Relaxinexpressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007; 67(9):4399-407.
105. Haviv YS, Blackwell JL, Li H, Wang M, Lei X, Curiel DT. Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res 2001; 61(23):8361-5.
106. Huang XF, Ren W, Rollins L, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res 2003; 63(21):7321-9.
107. Carette JE, Overmeer RM, Schagen FH, et al. Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 2004; 64(8):2663-7.
108. Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 2006; 66(19):9736-43.
109. Nakamori M, Fu X, Meng F, et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003; 9(7):2727-33.
110. Geoerger B, van Beusechem VW, Opolon P, et al. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 2005; 7(5):584-94.
111. van Beusechem VW, Mastenbroek DC, van den Doel PB, et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther 2003; 10(23):1982-91.
112. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8(3):449-58.
113. Fujiwara T, Kagawa S, Kishimoto H, et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP 401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 2006; 119(2):432-40.
114. Barton KN, Xia X, Yan H, et al. A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. Mol Ther 2004; 9(4):625-31.
115. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003; 77(16):8843-56.
116. Liu Y, Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther 2006; 13(9):845-55.
117. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes. Gene Ther 2006; 13(16):1235-43.